Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

Press Releases

BioSenic fait le point sur la préparation des comptes annuels et du rapport annuel pour l'exercice clos le 31 décembre 2024

  • Read more about BioSenic fait le point sur la préparation des comptes annuels et du rapport annuel pour l'exercice clos le 31 décembre 2024

BioSenic fait le point sur la préparation des comptes annuels et du rapport annuel pour l'exercice clos le 31 décembre 2024.

Le plan d'homologation de Biosenic approuvé par le Tribual de l'Entreprise et nomination de 2 administrateurs indépendants

  • Read more about Le plan d'homologation de Biosenic approuvé par le Tribual de l'Entreprise et nomination de 2 administrateurs indépendants

Le plan d'homologation de Biosenic approuvé par le Tribual de l'Entreprise pour restructurer plus de 22 millions d'euros de dette  et nomination de 2 administrateurs indépendants

BioSenic announces the homologation by the Enterprise Court of BioSenic's amicable agreements with five main creditors to restructure over €22 million of debt and appointment of two new independent directors

  • Read more about BioSenic announces the homologation by the Enterprise Court of BioSenic's amicable agreements with five main creditors to restructure over €22 million of debt and appointment of two new independent directors

BioSenic announces the homologation by the Enterprise Court of

BioSenic's amicable agreements with five main creditors to restructure over €22 million of debt and appointment of two new independent directors

 

BioSenic announces partnership with 4Moving Biotech and secures its financing.

  • Read more about BioSenic announces partnership with 4Moving Biotech and secures its financing.

BioSenic announces partnership with 4Moving Biotech to join forces to codevelop 4P004v, first-in-class GLP-1-based disease modifying drug for post-ligament surgery in dogs and the securing of its financing for the coming months by means of an amendment to its convertible bonds agreement.

BioSenic annonce un partenariat avec 4Moving Biotech et sécurise ses financements.

  • Read more about BioSenic annonce un partenariat avec 4Moving Biotech et sécurise ses financements.

BioSenic annonce un partenariat avec 4Moving Biotech afin d’unir leurs forces pour le co-développement de 4P004v, un médicament à base de GLP-1, premier de sa classe, destiné à modifier l’évolution de la maladie après une chirurgie ligamentaire chez le chien et avoir sécurisé son financement pour les mois à venir grâce à un avenant à son accord sur les obligations convertibles.

Biosenic finalise la restructuration de sa dette

  • Read more about Biosenic finalise la restructuration de sa dette

Biosenic finalise la restructuration de sa dette.

Biosenic pursues the restructuration of its debt.

  • Read more about Biosenic pursues the restructuration of its debt.

Biosenic pursues the restructuration of its debt.

Communication du nouveau dénominateur

  • Read more about Communication du nouveau dénominateur

COMMUNCATION OF THE NEW DENOMINATOR

  • Read more about COMMUNCATION OF THE NEW DENOMINATOR

BioSenic announces efforts to explore new strategic assets and partnerships in order to pursue its development following its recent debt restructuring

  • Read more about BioSenic announces efforts to explore new strategic assets and partnerships in order to pursue its development following its recent debt restructuring

BioSenic announces efforts to explore new strategic assets and partnerships in order to pursue its development following its recent debt restructuring

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to Press Releases
Wallonie Eu Flag

BioSenic SA
Avenue Léon champagne, 3
1480 Saintes – Belgium
info@biosenic.com
 

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions